Cemiplimab-rwlc Approved in Advanced Cutaneous Squamous Cell Carcinoma

被引：0
|
作者：
Schuyler, Devon
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：707 / 707
页数：1
相关论文
共 50 条
  • [41] Advanced cutaneous squamous cell carcinoma of the head in two renal transplanted patients treated with cemiplimab
    Orte Cano, C.
    Van Meerhaeghe, T.
    Tannous, J.
    Lienard, D.
    Van Gestel, D.
    Cuylits, N.
    Luce, S.
    Carlot, S.
    Le Moine, A.
    Aspeslagh, S.
    del Marmol, V.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 : 53 - 58
  • [42] Cemiplimab: A Review in Advanced Cutaneous Squamous Cell Carcinoma (vol 80, pg 813, 2020)
    Lee, Arnold
    Duggan, Sean
    Deeks, Emma D.
    DRUGS, 2020, 80 (09) : 939 - 939
  • [43] Cemiplimab and ruxolitinib in concomitant cutaneous squamous cell carcinoma and myelofibrosis
    Di Raimondo, Cosimo
    Rao, Ludovico
    Lozzi, Flavia
    Lombardo, Paolo
    Silvaggio, Dionisio
    Vellucci, Laura
    Tofani, Lorenzo
    Campione, Elena
    Bianchi, Luca
    DERMATOLOGIC THERAPY, 2022, 35 (05)
  • [44] Cemiplimab and Cutaneous Squamous Cell Carcinoma: From Bench to Bedside
    Goodman, D. T.
    JPRAS OPEN, 2022, 33 : 155 - 160
  • [45] Successful Administration of Cemiplimab to a Patient With Advanced Cutaneous Squamous Cell Carcinoma After Renal Transplantation
    Ali, Saad Ahmad
    Arman, Huseyin Emre
    Patel, Anuj Amrut
    Birhiray, Ruemu Ejedafeta
    JCO ONCOLOGY PRACTICE, 2020, 16 (03) : 137 - +
  • [46] Identifying candidates for immunotherapy with cemiplimab to treat advanced cutaneous squamous cell carcinoma: an expert opinion
    Argenziano, Giuseppe
    Fargnoli, Maria Concetta
    Fantini, Fabrizio
    Gattoni, Massimo
    Gualdi, Giulio
    Pastore, Francesco
    Pellacani, Giovanni
    Quaglino, Pietro
    Queirolo, Paola
    Troiani, Teresa
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2022, 14
  • [47] Cemiplimab for locally advanced cutaneous squamous cell carcinoma: safety, efficacy, and position in therapy panel
    Lebas, Eve
    Marchal, Nathalie
    Rorive, Andree
    Nikkels, Arjen F.
    EXPERT REVIEW OF ANTICANCER THERAPY, 2021, 21 (04) : 355 - 363
  • [48] Cemiplimab in advanced cutaneous squamous cell carcinoma: the UK experience from the Named Patient Scheme
    Challapalli, A.
    Watkins, S.
    Cogill, G.
    Stewart, G.
    Ellis, S.
    Sykes, A.
    Nobes, J.
    Yip, K.
    Barthakur, U.
    Board, R.
    Gadve, A.
    O'Toole, L.
    Kent, C.
    Mackenzie, J.
    Papa, S.
    Fusi, A.
    Fife, K.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2022, 36 (07) : E590 - E592
  • [49] Use of cemiplimab in locally advancesd cutaneous squamous cell carcinoma
    Schaffer, M.
    Asna, N.
    Livof, A.
    Simanovich, A.
    Ostfeld, I
    STRAHLENTHERAPIE UND ONKOLOGIE, 2020, 196 (SUPPL 1) : S77 - S78
  • [50] Comparative efficacy of cemiplimab versus other systemic treatments for advanced cutaneous squamous cell carcinoma
    Keeping, Sam
    Xu, Yingxin
    Chen, Chieh-, I
    Cope, Shannon
    Mojebi, Ali
    Kuznik, Andreas
    Konidaris, Gerasimos
    Ayers, Dieter
    Sasane, Medha
    Allen, Rachel
    Huynh, Thi-Minh-Thao
    Popoff, Evan
    Freeman, Morganna
    Andria, Michael L.
    Fury, Matthew G.
    Singh, Kanwarjit
    Stockfleth, Eggert
    Challapalli, Amarnath
    Schmults, Chrysalyne D.
    FUTURE ONCOLOGY, 2021, 17 (05) : 611 - 627
12345